Artificial intelligence and psychedelic medicine

Artificial intelligence (AI) and psychedelic medicines are among the most high‐profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine i...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2024-10, Vol.1540 (1), p.5-12
Main Authors: Sarris, Jerome, Halman, Andreas, Urokohara, Anna, Lehrner, Mathew, Perkins, Daniel
Format: Article
Language:English
Subjects:
Algorithms
Artificial intelligence
Brain
Cognitive ability
computational psychiatry
Computer applications
Design optimization
disruptive innovation
DMT
Drug development
Ethics
Health services
machine learning
Mental health
natural language processing
Neural networks
Pharmacodynamics
psilocybin
Psychedelic drugs
Security
Virtual reality
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Artificial intelligence (AI) and psychedelic medicines are among the most high‐profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. In order to inform our perspective, we conducted a scoping review of relevant literature up to late August 2024 via PubMed intersecting AI with psychomedical use of psychedelics. Our perspective covers the potential application of AI in psychedelic medicine for: drug discovery and clinical trial optimization (including pharmacodynamics); study design; understanding psychedelic experiences; personalization of treatments; clinical screening, delivery, and follow‐up (potentially delivered via chatbots/apps); application of psychological preparation, integration, and general mental health support; its role in enhancing treatment via brain modulatory devices (including virtual reality and haptic suits); and the consideration of ethical and security safeguards. Challenges include the need for sufficient data protection and security, and a range of necessary ethical protections. Future avenues of exploration could involve directly administering psychedelics (or providing algorithm‐generated effects) to inorganic AI‐interfaced neural networks that may exceed human brain activity (i.e., cognitive capacity) and intelligence.
ISSN:0077-8923
1749-6632
1749-6632
DOI:10.1111/nyas.15229